GlassScriptPhysician profile
Khalid Mohamed
NPI 1386094944
$1,213.82
in general payments reported to CMS, 2019-2025
18 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $144 · 2023: $307 · 2024: $227 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $330.58 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $119.20 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $101.07 | 2022-2025 | Jynarque, Voyxact |
| Alexion Pharmaceuticals, INC. | $99.99 | 2024 | Soliris |
| Aurinia Pharma U.S., INC. | $93.43 | 2022-2023 | Lupkynis |
| Travere Therapeutics, INC. | $69.86 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $56.19 | 2025 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.10 | 2025 | Jardiance |
| Nxstage Medical, INC. | $49.20 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $39.60 | 2024-2025 | Farxiga |
| Vifor Pharma, INC. | $39.57 | 2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $30.67 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.72 | 2025 | |
| Glaxosmithkline, LLC. | $21.84 | 2024 | Benlysta |
| Lilly USA, LLC | $21.80 | 2025 | Jardiance |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $20.74 | 2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $19.30 | 2024 | Camzyos |
| Amgen INC. | $16.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Mohamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.